Published in AIDS Res Hum Retroviruses on September 01, 2008
High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis (2011) 2.10
Viral Genetic Diversity and Polymorphisms in a Cohort of HIV-1-Infected Patients Eligible for Initiation of Antiretroviral Therapy in Abuja, Nigeria. AIDS Res Hum Retroviruses (2015) 0.81
The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res (1997) 175.36
inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science (1994) 11.22
Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci U S A (1991) 10.05
Consensus sequences as substrate specificity determinants for protein kinases and protein phosphatases. J Biol Chem (1991) 8.03
p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J Virol (1995) 6.87
AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell (2003) 6.69
Interactive analysis of phylogeny and character evolution using the computer program MacClade. Folia Primatol (Basel) (1989) 6.35
A role for ubiquitin ligase recruitment in retrovirus release. Proc Natl Acad Sci U S A (2000) 4.19
Evidence for positive epistasis in HIV-1. Science (2004) 4.12
Fine mapping and characterization of the Rous sarcoma virus Pr76gag late assembly domain. J Virol (1996) 3.97
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
A proline-rich motif (PPPY) in the Gag polyprotein of Mason-Pfizer monkey virus plays a maturation-independent role in virion release. J Virol (1998) 3.69
Mutations altering the moloney murine leukemia virus p12 Gag protein affect virion production and early events of the virus life cycle. EMBO J (1999) 3.67
The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner. J Virol (2002) 2.66
The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles. J Virol (1995) 2.64
Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc Natl Acad Sci U S A (1998) 2.23
Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy. Nat Med (2002) 2.13
A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J Virol (1995) 1.93
A conserved LXXLF sequence is the major determinant in p6gag required for the incorporation of human immunodeficiency virus type 1 Vpr. J Virol (1996) 1.47
Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. Eur J Biochem (2002) 1.30
Role of the C terminus Gag protein in human immunodeficiency virus type 1 virion assembly and maturation. J Gen Virol (1995) 1.29
Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program. J Acquir Immune Defic Syndr (2005) 1.26
Proline residues in human immunodeficiency virus type 1 p6(Gag) exert a cell type-dependent effect on viral replication and virion incorporation of Pol proteins. J Virol (1999) 1.23
Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein. J Virol (2001) 1.22
Mutations of the human immunodeficiency virus type 1 p6Gag domain result in reduced retention of Pol proteins during virus assembly. J Virol (1998) 1.20
The host cell MAP kinase ERK-2 regulates viral assembly and release by phosphorylating the p6gag protein of HIV-1. J Biol Chem (2004) 1.14
Inclusion of full length human immunodeficiency virus type 1 (HIV-1) gag sequences in viral recombinants applied to drug susceptibility phenotyping. J Virol Methods (2002) 1.13
Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1. J Virol (2005) 1.11
Incorporation of Vpr into human immunodeficiency virus type 1: role of conserved regions within the P6 domain of Pr55gag. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.10
Analysis of insertions and deletions in the gag p6 region of diverse HIV type 1 strains. AIDS Res Hum Retroviruses (2004) 1.05
The late-domain-containing protein p6 is the predominant phosphoprotein of human immunodeficiency virus type 1 particles. J Virol (2002) 1.04
Subtype-specific patterns in HIV Type 1 reverse transcriptase and protease in Oyo State, Nigeria: implications for drug resistance and host response. AIDS Res Hum Retroviruses (2006) 1.02
Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pretreated patients. J Clin Microbiol (2003) 0.98
Genetic mechanisms of resistance to NRTI and NNRTI. HIV Clin Trials (2002) 0.90
Evolution. Epistasis in RNA viruses. Science (2004) 0.88
Differences in the length of gag proteins among different HIV type 1 subtypes. AIDS Res Hum Retroviruses (2005) 0.87
Analysis of PTAP duplications in the gag p6 region of subtype C HIV type 1. AIDS Res Hum Retroviruses (2005) 0.79
Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS Med (2009) 4.34
Integrated Modeling Program, Applied Chemical Theory (IMPACT). J Comput Chem (2005) 3.71
Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis (2006) 3.03
Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr (2007) 2.61
Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis (2011) 2.15
Highly active antiretroviral therapy and viral response in HIV type 2 infection. Clin Infect Dis (2004) 1.68
Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis (2009) 1.52
Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol (2005) 1.48
A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy. Clin Infect Dis (2012) 1.46
The marriage of science and optimized HIV care in resource-limited settings. AIDS (2008) 1.44
Preferential in-utero transmission of HIV-1 subtype C as compared to HIV-1 subtype A or D. AIDS (2004) 1.41
Transmission of cell-free and cell-associated HIV-1 through breast-feeding. J Acquir Immune Defic Syndr (2006) 1.38
Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa. Int J Cancer (2013) 1.38
Severity and cost of unsafe abortion complications treated in Nigerian hospitals. Int Fam Plan Perspect (2008) 1.37
Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. Stat Med (2003) 1.26
Dolutegravir for the treatment of HIV. Expert Opin Investig Drugs (2012) 1.20
Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis (2007) 1.17
Comparison of a DNA based PCR method with conventional methods for the detection of M. tuberculosis in Jos, Nigeria. J Infect Dev Ctries (2009) 1.16
Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol (2007) 1.16
Twenty years of prospective molecular epidemiology in Senegal: changes in HIV diversity. AIDS Res Hum Retroviruses (2007) 1.15
Intrapatient diversity and its correlation with viral setpoint in human immunodeficiency virus type 1 CRF02_A/G-IbNG infection. J Virol (2002) 1.14
Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr (2004) 1.12
Genetic diversity of Mycobacterium tuberculosis Complex in Jos, Nigeria. BMC Infect Dis (2010) 1.09
Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F. J Infect Dis (2008) 1.07
Robust classification of subcellular location patterns in high resolution 3D fluorescence microscope images. Conf Proc IEEE Eng Med Biol Soc (2004) 1.06
Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. J Infect Dis (2013) 1.06
Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. PLoS One (2012) 1.06
Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr (2013) 1.05
NeuroAIDS in Africa. J Neurovirol (2010) 1.05
Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. J Acquir Immune Defic Syndr (2009) 1.05
Emerging sociodemographic and lifestyle predictors of intention to use condom in human immunodeficiency virus intervention among uniformed services personnel. Mil Med (2006) 1.05
Distinct human immunodeficiency virus type 1 subtype A virus circulating in West Africa: sub-subtype A3. J Virol (2004) 1.05
Objective screening for cervical cancer in developing nations: lessons from Nigeria. Gynecol Oncol (2007) 1.02
The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals. AIDS Res Hum Retroviruses (2008) 1.02
Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. J Clin Endocrinol Metab (2003) 1.02
Subtype-specific patterns in HIV Type 1 reverse transcriptase and protease in Oyo State, Nigeria: implications for drug resistance and host response. AIDS Res Hum Retroviruses (2006) 1.02
Genomic sites of human immunodeficiency virus type 2 (HIV-2) integration: similarities to HIV-1 in vitro and possible differences in vivo. J Virol (2006) 1.00
Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. PLoS One (2013) 1.00
Comparison of a new, affordable flow cytometric method and the manual magnetic bead technique for CD4 T-lymphocyte counting in a northern Nigerian setting. Clin Diagn Lab Immunol (2005) 0.99
Leukocytes regulate retinal capillary degeneration in the diabetic mouse via generation of leukotrienes. J Leukoc Biol (2012) 0.98
Hypermutation of HIV type 1 genomes isolated from infants soon after vertical infection. AIDS Res Hum Retroviruses (2003) 0.98
Condom use among antiretroviral therapy patients in Ibadan, Nigeria. J Infect Dev Ctries (2010) 0.98
HIV type 1 subtypes among bar and hotel workers in Moshi, Tanzania. AIDS Res Hum Retroviruses (2003) 0.97
Human papillomavirus infection in women with and without cervical cancer in Ibadan, Nigeria. Infect Agent Cancer (2010) 0.96
A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings. J Neurovirol (2011) 0.96
Effectiveness of a video-based motivational skills-building HIV risk-reduction intervention for female military personnel. Soc Sci Med (2010) 0.95
Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients. AIDS (2008) 0.95
A brief assessment of learning for orphaned and abandoned children in low and middle income countries. AIDS Behav (2012) 0.93
Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. J Infect Dis (2013) 0.93
Accuracy of optical spectroscopy for the detection of cervical intraepithelial neoplasia without colposcopic tissue information; a step toward automation for low resource settings. J Biomed Opt (2012) 0.93
Viral dynamics of primary HIV-1 infection in Senegal, West Africa. J Infect Dis (2005) 0.92
Motivational groups support adherence to antiretroviral therapy and use of risk reduction behaviors in HIV positive Nigerian women: a pilot study. Afr J Reprod Health (2012) 0.91
Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting. J Antimicrob Chemother (2012) 0.91
Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes. Antivir Ther (2009) 0.91
Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1. Curr HIV Res (2010) 0.90
Short communication: Transmitted HIV drug resistance in antiretroviral-naive pregnant women in north central Nigeria. AIDS Res Hum Retroviruses (2013) 0.89
Enhancement of health research capacity in Nigeria through north-south and in-country partnerships. Acad Med (2014) 0.89
Molecular epidemiology of human immunodeficiency virus type 1 sub-subtype A3 in Senegal from 1988 to 2001. J Virol (2004) 0.89
Influence of educational status and other variables on human immunodeficiency virus risk perception among military personnel: a large cohort finding. Mil Med (2007) 0.89
HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. AIDS (2002) 0.89
HIV type 1 circulating recombinant form CRF09_cpx from west Africa combines subtypes A, F, G, and may share ancestors with CRF02_AG and Z321. AIDS Res Hum Retroviruses (2004) 0.89
Structural studies of several clinically important oncology drugs in complex with human serum albumin. Biochim Biophys Acta (2013) 0.88
Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort. World J Gastroenterol (2013) 0.87
Community attitudes towards childbearing and abortion among HIV-positive women in Nigeria and Zambia. Cult Health Sex (2012) 0.87
Correlates of HIV knowledge and sexual risk behaviors among female military personnel. AIDS Behav (2010) 0.87
Predictors of frequency of condom use and attitudes among sexually active female military personnel in Nigeria. HIV AIDS (Auckl) (2010) 0.86
A 5'UTR-spliced mRNA isoform is specialized for enhanced HIV-2 gag translation. J Mol Biol (2009) 0.85
Adherence to antiretroviral therapy in resource-limited settings: everything matters. AIDS (2007) 0.84
An application of exposure modeling in exposure assessments for a university chemistry teaching laboratory. J Occup Environ Hyg (2006) 0.83
Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1. J Med Virol (2012) 0.83
High-risk human papillomavirus among HIV-infected women with normal cervical cytology: a pilot study in Jos, Nigeria. Arch Gynecol Obstet (2013) 0.82
Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria. AIDS (2015) 0.82
High prevalence of toxinogenic Clostridium difficile in Nigerian adult HIV patients. Trans R Soc Trop Med Hyg (2011) 0.82
Persistent pulmonary hypertension results in reduced tetralinoleoyl-cardiolipin and mitochondrial complex II + III during the development of right ventricular hypertrophy in the neonatal pig heart. Am J Physiol Heart Circ Physiol (2011) 0.82
A comparative effectiveness review of parenting and trauma-focused interventions for children exposed to maltreatment. J Dev Behav Pediatr (2013) 0.82
Attitudes of women and men living with HIV and their healthcare providers towards pregnancy and abortion by HIV-positive women in Nigeria and Zambia. Afr J AIDS Res (2015) 0.81
Optimizing treatment switch for virologic failure during first-line antiretroviral therapy in resource-limited settings. J Int Assoc Provid AIDS Care (2012) 0.81